2019 Volume 52 Issue 12 Pages 753-763
Purpose: We investigated the efficacy and safety of neoadjuvant chemoradiotherapy with docetaxel and 5-fluorouracil (DF-NACRT) followed by esophagectomy to treat advanced esophageal cancer. Methods: We reviewed data from 12 patients with advanced esophageal cancer who underwent trimodality therapy comprising DF-NACRT followed by esophagectomy between December 2007 and August 2017. Results: Patients consisted of cStage II: 2 patients, III: 1 patient, IVA: 8 patients, IVB: 1 patient, and the median age was 68 years [range, 50–82]. Hematologic toxicity and non-hematological toxicity (≥Grade 2) was observed in 4 (33.3%) and 6 patients (50%), respectively. Four patients (33.3%) had complete pathologic responses (pCR) of the primary tumor, and the T or N status was also down-staged in 9 patients (75%). Mortality due to postoperative morbidity was zero. Conclusions: This regimen with docetaxel and 5-fluorouracil is promising as a safe and effective neoadjuvant chemoradiotherapy for esophageal cancer.
